{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-000078","form_type":"8-K","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.635382+00:00","generated_at":"2026-06-20T18:39:42.920598+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"confidence":"low","headline":"Sonoma Pharmaceuticals updates investor presentation; no material new disclosures","bullets":["Presentation highlights stabilized hypochlorous acid products for dermatology, wound care, eye care, and other applications.","Company reports distribution in 55 countries via direct sales and partners.","No financial results, guidance, or material operational changes were announced.","Contains forward-looking statements with usual risk factors.","Filing is a routine Regulation FD disclosure of an updated corporate overview."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-000078","json":"https://secwatch.observer/filing/0001683168-23-000078.json","markdown":"https://secwatch.observer/filing/0001683168-23-000078.md","text":"https://secwatch.observer/filing/0001683168-23-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823000078/0001683168-23-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823000078/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:39:42.920598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}